A Phase IV, Multi-Center, Open-Label Study of DAYTRANA (Methylphenidate Transdermal System [MTS]) to Characterize the Dermal Reactions in Pediatric Patients Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)

Trial Profile

A Phase IV, Multi-Center, Open-Label Study of DAYTRANA (Methylphenidate Transdermal System [MTS]) to Characterize the Dermal Reactions in Pediatric Patients Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Sponsors Noven Pharmaceuticals; Shire
  • Most Recent Events

    • 08 Apr 2009 Actual patient number (309) added as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Actual end date changed from Aug 2007 to Jul 2008 as reported by ClinicalTrials.gov.
    • 24 Aug 2008 Actual end date changed from Jul 2007 to Aug 2005 as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top